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A B S T R A C TObjectives: Hepatitis C therapy in Brazil is expensive due to the cost
of antiviral drugs and demands on medical resources. The objective of
this study was to estimate the direct costs per patient of chronic
hepatitis C therapy in a Brazilian setting. Method: A microcosting
study from a public health system perspective. The costs included
were those of antiviral drugs, secondary medicines, diagnostic tests,
visits to physicians and other professionals, hospitalization, nurse,
and pharmaceutical care. All costs were priced in 2010. The values
were converted to US $ (2010). Results: The total direct cost of
hepatitis C treatment per patient with interferon alpha (IFN) plus
ribavirin (RBV) was US $982.25, with peginterferon alpha (PEG) 2a 180
mg plus RBV was US $10,658.08, and with PEG 2b 120 mg plus RBV was
US $12,597.63, taking into account entire treatment according to
Brazilian guidelines and assuming that all patients completed fullnt matter Copyright & 2012, International Society
r Inc.
.1016/j.vhri.2012.10.001
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al de Santa Catarina, Campus Universita´rio Trindatreatment. The antiviral drugs are the most expensive element of the
cost of treatment, totaling more than 40% of the medical costs of IFN
plus RBV therapy and more than 88% of PEG plus RBV therapy.
Calculating an average of 10,000 treatments per year, the total direct
cost is US $90,346,772.39. According to the Ministry of Health, 90% of
the annual total cost of hepatitis C treatment is accounted for by
antiviral drugs. Conclusions: In Brazil, antiviral drugs are the most
expensive component of hepatitis C treatment. The cost of follow-up
and support to patients is minimal compared with the cost of
antiviral drugs.
Keywords: direct cost, hepatitis C, hepatitis C treatment, interferon.
Copyright & 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Infectious diseases are a very significant public health issue in
Brazil, not only in terms of overall morbidity but also due to the
financial burden and extra demands placed on medical resources
[1–3].
Hepatitis C virus (HCV) infection is a serious public health
problem as 80% to 85% of HCV carriers develop a persistent
infection. Cirrhosis, end-stage liver disease, and hepatocellular
carcinoma are the most significant clinical consequences of
chronic HCV infection [4]. Moreover, patients with chronic HCV
infection require periodic ambulatory care to monitor and treat
their condition. As a result, studies show that patients with
chronic HCV infection [5] consume a substantial and escalating
amount of health care resources.
Treatment for 24 or 48 weeks with interferon alpha (IFN)
or peginterferon alpha (PEG) is recommended for people with
HCV infection, according to viral and clinical characteristics.The primary aim of treating chronic hepatitis C is to clear HCV,
in order to improve quality of life and reduce the risk of cirrhosis
and hepatocellular carcinoma [6].
In Brazil, the public health system provides treatment for
chronic HCV infection, including the use of IFN, PEG, and
ribavirin (RBV). In 2007, the amount allocated to drugs in the
Brazilian Ministry of Health budget was 10.7% and the specialized
component of pharmaceutical services accounted for 42% of this
expenditure [7]. Another study revealed that Brazil’s national
system to treat hepatitis C had an annual budget of US
$14,553,293.90 in 2002 and US $31,633,149.41 in 2007 for medi-
cines [8].
The treatment of HCV infection is expensive and almost 50%
of all patients who undergo this treatment are not cured,
representing a low cost-effectiveness ratio. The treatment can
cause many side effects such as flu-like symptoms, fatigue,
hemolytic anemia, neutropenia, depression, irritability, concen-
tration loss and memory disturbances, skin irritation, and weightfor Pharmacoeconomics and Outcomes Research (ISPOR).
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adherence [10].
Available data indicate that patients who are adherent and
receive at least 80% of their total PEG and RBV doses for at least
80% of the duration of treatment have significantly higher rates
of sustained viral response (SVR) when compared with patients
with lower levels of adherence [11]. Studies show that patients
are more likely to adhere to and complete therapy when there is
ongoing support by a clinical team [12].
In a systematic review of studies of treatment of chronic HCV
infection in Brazil, the rates of discontinuation varied between
4.5% and 44.4%. Meta-regression to evaluate the association
between rates of no SVR and rates of noncompletion found a
linear association and demonstrated that an increase of 10% in
the discontinuation rate decreased SVR by 4.1%. According to this
analysis, discontinuation of treatment is a major reason for the
observed differences in rates of SVR in clinical settings compared
with clinical trials [13].
In view of the fact that the rate of treatment discontinuation
is indirectly related to service organization, this study aims to
estimate the cost of chronic HCV infection therapy in a Brazilian
setting from the perspective of the Brazilian National Health
System. The subject of this study was a group of patients treated
in a specialist public health center for HCV infection, cared for by
a multidisciplinary team in accordance with Brazilian guidelines.Methods
A microcosting study from the perspective of the Brazilian public
health system was carried out to identify the direct cost of
treatment per patient. The study included the cost of antiviral
drugs, treatment of side effects, diagnostic tests, the administra-
tion of injectable drugs, outpatient visits to specialist physicians
and other professionals, and hospitalization due to treatment.
These costs were estimated taking into account the entire
treatment in accordance with Brazilian guidelines and assuming
that all patients completed full treatment.Antiviral Drugs
The antiviral drugs and the duration of treatment were estimated
according to Brazilian guidelines [14], and the costs of IFN, PEG,
and RBV were those used by the Ministry of Health in 2010. These
drugs were purchased through a public bidding process organized
by the Ministry of Health.Treatment of Side Effects
The drugs used by patients to control side effects and their
duration of use in the HCV infection therapy were identified from
the prospective cohort study that was carried out in a specialist
public health center in Florianopolis between 2005 and 2008 with
111 patients. A multidisciplinary team monitored patients
weekly. Data were collected by a pharmacist who monitored
patients [15].
The drugs used to treat the side effects resulting from HCV
infection treatment were divided into two groups. The first
included epoetin alpha and colony-stimulating factor for the
control of anemia and neutropenia. The second group included
other drugs to control side effects such as fatigue, headache,
myalgia, rigors, fever, nausea, insomnia, and depression. The
costs of epoetin alpha and colony-stimulating factor are based on
Ministry of Health figures. The costs of others drugs are based on
figures from the municipality of Florianopolis.Diagnostics Tests
The diagnostic tests for HCV infection were identified according
to Brazilian guidelines [14]. The diagnostic tests were divided into
initial tests and monitoring tests. The initial diagnostic tests
included blood cell count, platelet count, alanine transaminase,
aspartate transaminase, protronbin time, bilirubin, albumin,
creatinine, uric acid, fasting glucose, thyroid–stimulating hor-
mone, anti-HIV, antigen of the hepatitis B virus, beta human
chorionic gonadotropin (women), liver biopsy, HCV genotyping,
HCV gene quantitative for patients and use of PEG, and qualitative
HCV. The follow-up diagnostic (monitoring) tests included com-
plete blood cell count, platelet count, alanine transaminase,
aspartate transaminase, creatinine, thyroid-stimulating hormone,
HCV qualitative, and HCV quantitative [14]. The cost of diagnostic
tests was taken from the Ministry of Health’s database [16].
Administration of Injectable Drugs
According to Brazilian guidelines, all patients undergoing HCV
infection treatment should have medication administered in
specialist clinics [17]. Therefore, it was assumed that all patients
underwent the administration of injectable drugs in specialist
clinics and the cost of this procedure was taken from the Ministry
of Health database [16].
Outpatient Visits to Specialist Physicians and Other
Professionals
Visits to specialist physicians for routine follow-ups were esti-
mated according to Brazilian guidelines [14]. Nursing care was
calculated according to the frequency of the administration
of injectable drugs. Pharmaceutical follow-ups were calculated
monthly during the period of treatment. Outpatient visits to other
professionals were estimated by using the prospective cohort of
patients [18]. The cost of outpatient visits to physicians and other
professionals was taken from the Ministry of Health database [16].
Hospitalizations
The number of hospitalizations associated with HCV infection
treatment was identified in a retrospective cohort [18]. The data
were identified from the medical records of 188 patients who
received treatment between 2003 and 2006 at a specialist clinic in
Florianopolis. The cost of treating each patient was calculated
according to the procedures described on the patient record. The
cost was taken from the public health system database for
hospital procedures [16]. The average cost of hospitalization per
day was calculated by dividing the cost of all hospitalizations for
full-time care by the number of days of hospitalization.
Our methodological approach set out to 1) identify the
resources used, b) estimate costs from a public health system
perspective, c) calculate the cost per patient, and D) calculate the
Ministry of Health’s estimated expenditure.
All resources identified were multiplied by the probability of
being used by patients. The sum of the total costs is equivalent to
the total direct cost taking into account all patients who received
full treatment. All costs were based on prices from 2010. The
figures were converted to US $ (2010), R $1.00 ¼ US $0.57,
according to the exchange rate on July 30, 2010 [19].
Data on the number of patients with HCV infection in Brazil
between 2000 and 2009 were compiled according to the epide-
miologic database [20]. The number of patients who have under-
gone HCV infection treatment in Brazil was estimated according
to the number of units of IFN and PEG distributed by the Ministry
of Health. By taking the number of patients diagnosed and
treated annually in Brazil, we can estimate the annual budget
to treat patients with HCV infection in Brazil.
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Antiviral Drugs
According to Brazilian guidelines for treatment-naive and
genotype 1 patients, the recommended treatment is PEG 2a 180
mg or PEG 2b 1.5 mg/kg, administered subcutaneously once a
week, in conjunction with RBV 1000 mg/day for patients weighing
less than 75 kg or RBV 1250 mg/day for patients weighing 75 kg or
more, for a period of 48 weeks if patients present an early
virologic response (EVR) (negative polymerase chain reaction–HCV
or drop of 2 logs in viral load from baseline) in week 12 of
treatment. Patients co-infected with HCV-HIV may undergo the
same therapeutic regimen for a period of 48 weeks regardless of
genotype [14].
Naive patients with genotype 2 or 3 are treated with IFN 2a or
2b 3MU administered subcutaneously three times a week in
conjunction with RBV 1000 mg/day for patients weighing less
than 75 kg, or RBV 1250 mg/day for patients weighing 75 kg or
more, for a period of 24 weeks [14].
Brazilian guidelines, revised in 2011, state that all relapse or
nonresponder patients to previous HCV infection treatment can
undergo a second course of treatment with PEG plus ribavirin for
48 weeks, irrespective of genotype. They also state that patients
with genotype 2 or 3, and with cirrhosis or a Metavir score of F3
or F4, can undergo treatment with PEG plus RBV. Furthermore,
there is a provision for 72 weeks of treatment for those patients
who only obtain a negative polymerase chain reaction–HCV or a
drop of 2 logs in viral load from baseline in week 24 of treatment
[17].
The cost of antiviral drugs per patient to complete the
treatment is US $303.29 for IFN, for 24 weeks of treatment; US
$9447.68 for PEG 2a 180 mg and US $11,387.23 for PEG 2b 120 mg, for
48 weeks of treatment.Treatment of Side Effects
For treatment with PEG, the prevalence of the use of epoetin
alpha was 31% with a range of use between 1 and 39 weeks. The
median dose per week was 14,000 UI (10,000–42,500). The pre-
valence of the use of the colony-stimulating factor was 20% with
a range of use of between 1 and 41 weeks. The median dose per
week was 300 UI (300–525). As IFN treatment is for 24 weeks, half
of this use was estimated. Therefore, the cost of epoetin alpha
and colony-stimulating factor for PEG treatment is US $316.01
and for IFN treatment is US $158.00.Fig. 1 – Percentage of total direct cost for treatment of hepatitis C
2a 180 lg plus ribavirin. IFN, interferon alpha; PEG, peginterferAnalgesics and antidepressives are the medications most
commonly used for treating side effects. The cost of these drugs
is US $3.39 for PEG treatment and US $1.69 for IFN treatment.
Diagnostics Tests
The cost of initial diagnostic tests for IFN treatment is US $260.23
and for PEG treatment is US $356.26. The cost of follow-up
diagnostic tests for IFN treatment is US $91.02 and for PEG
treatment is US $249.69.
Administration of Injectable Drugs
For injectable drugs it was assumed that all patients underwent
this treatment in specialist clinics three times a week for 24
weeks for treatment with IFN plus RBV and once a week for 48
weeks for treatment with PEG plus RBV. The cost of administering
injectable drugs for IFN treatment is US $25.86 and for PEG
treatment is US $17.24.
Outpatient Visits to Specialist Physicians and Other
Professionals
It was estimated that there were at least five visits to a physician for
treatment with IFN plus RBVand seven for treatment with PEG plus
RBV. The costs were US $28.50 and US $39.90, respectively.
Other patient referrals for treating side effects during antiviral
therapy included dermatology, nutrition, and psychiatric care.
The costs for IFN treatment and for PEG treatment were US $1.30
and US $2.62, respectively.
The cost of pharmaceutical care for IFN treatment was US $21.55
and for PEG treatment was US $43.09. The cost of nursing care for
IFN treatment was US $86.18 and for PEG treatment was US $172.37.
Hospitalization
The prevalence of hospitalization in groups undergoing PEG
treatment was 4.3%, at an average cost of US $231.62. The total
cost of hospitalization per patient for IFN treatment was US $4.93
and for PEG treatment was US $9.86.
Total Annual Budget
The total direct cost of HCV infection treatment with IFN plus
RBV was US $982.25, with PEG 2a 180 mg plus RBV was US
$10,658.08, and with PEG 2b 120 mg plus RBV was US $12,597.63
(Table 1). The cost of treatment with PEG plus RBV was 10 times
the cost of treatment with IFN plus RBV.with interferon alpha plus ribavirin and peginterferon alpha
on alpha; RBV, ribavirin.
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the most expensive category in the treatment cost, amounting to
30.9% of medical costs in IFN therapy and 88.6% in PEG therapy.
According to data from the Ministry of Health, between 2007
and 2009, 10,000 patients were being treated per year; 21% of
these treatments were carried out with IFN plus RBV, 43% with
PEG 2a 180 mg plus RBV, and 36% with PEG 2b plus RBV.
Given an average of 10,000 treatments per year and our
estimate of costs for HCV infection treatment, the total direct
cost per year was US $93,243,937.00. The cost of treatment with
IFN plus RBV was US $2,062,725.00, with PEG 2a 180 mg plus RBV
was US $45,829,744.00, and with PEG 2b plus RBV was US
$45,351,468.00.
The costs were estimated assuming that all patients received
complete treatment. Given that the range of discontinuation of
therapy was between 4% and 44%, the total costs were reduced to
US $91,379,058.26 and US $72,730,270.86 respectively, when dis-
continuation occurs at 24 weeks with PEG and 12 weeks with IFN.
Treatment discontinuation, however, can lead to disease progres-
sion and an increase in costs.Discussion
Cost of Antiviral Drugs
The cornerstone of therapy is the use of injectable PEG prepara-
tions. They are expensive and carry the risk of severe side effects
and not all patients benefit from the treatment [21]. Data from
Brazil corroborate this. The major cost component of HCV
treatment is antiviral drugs. We found a great difference between
the total costs of treatment with IFN plus RBV compared with PEG
plus RBV (10 times higher). This could be around 31 times higher
when compared with the cost of antiviral drugs.
The high cost of antiviral drugs justifies the use of guidelines
to define the criteria to treat patients. Only those patients who
present characteristics that are more likely to result in successful
treatment should undergo this therapy. Therefore, further cost-
effectiveness analyses are necessary, in particular subgroup
analyses such as genotype and disease evolution.
Treatment of Side Effects
If we include costs of side effects of drugs, professional pharma-
ceutical and nursing care (excluding specialist physicians), and
hospitalization in the cost of the treatment, the total cost is US
$165.93 for IFN treatment and US $331.85 for PEG treatment.
Side effects are the most significant obstacles to adherence
[10]. Managing HCV infection treatment side effects is crucial to
maintaining or improving adherence and successfully concluding
treatment [12,22]. Preventing or correcting a therapy complica-
tion can increase the likelihood of adherence for patients and
may improve virologic response rates [23].
The most frequent reasons for withdrawal are depression or an
inability to tolerate side effects. Treatment cessation for neutrope-
nia, anemia, or thrombocytopenia is infrequent, although many
patients require dose reduction during treatment [10,24,25].
In Brazil, the number of patients who discontinue treatment
because of side effects is between 4% and 44% [13], and therefore
it is very important that patients undergoing HCV infection
treatment are followed up and side effects are managed.
The most expensive side-effect control is epoetin alpha and
colony-stimulating factor for the control of anemia and neutro-
penia. Although these agents are expensive, their use has
increased in clinical settings to enable patients to continue their
PEG plus RBV regimen and to sustain the RBV doses needed to
maximize chances of SVR [22].We found that 31% of the patients were treated with epoetin
alpha and 20% with colony-stimulating factor. In another study,
however, these figures were lower; 9% to 17% of the patients
receiving PEG were also receiving granulocyte colony-stimulating
factor or epoetin alpha [10].
Other drugs to control side effects are cheaper in comparison
to granulocyte colony-stimulating factor or epoetin alpha and
have advantages when used correctly as they can improve the
likelihood of completing the therapy.
Diagnostic Tests
Monitoring should include examination, determination of HCV
RNA levels, verification of adherence, and assessment for side
effects. Clinical and virologic monitoring should be conducted at
intervals ranging from once a month to once every 3 months [12].
Hematologic monitoring is recommended for detecting anemia,
neutropenia, or thrombocytopenia. Determination of thyroid-
stimulating hormone is also recommended for identifying hyper-
or hypothyroidism. Close monitoring for clinical signs of depres-
sion, with appropriate intervention, is of particular importance
[25]. Tests such as genotyping and viral load can help estimate
the likelihood of antiviral response and determine the duration of
therapy, and other tests should be carried out for baseline values
to monitor for potential side effects from therapy.
Monitoring of antiviral therapy is essential to maximize
benefit and ensure that complications that might interfere with
outcomes are prevented. Despite the fact that initial and follow-
up diagnostic tests are very important, we know that in Brazil
some patients have difficulty accessing them.
Diagnostic tests represent only 5.7% of the total direct cost of
treatment with PEG plus RBV and 35.7% of the total direct cost of
treatment with IFN plus RBV. This difference is due to the
considerable contrast in price between these antiviral drugs;
however, follow-up tests are cheaper for treatment with IFN plus
RBV than for treatment with PEG plus RBV.
Moreover, another important reason for monitoring treatment
is EVR. Clinical studies have shown that patients not achieving
EVR by 12 weeks of treatment, defined as at least a 2-log
reduction in HCV RNA levels, have only a small chance (o3%)
of achieving SVR at the end of a full course of therapy [22,25,26].
This ‘‘12-week stop rule’’ is particularly important for patients
with genotype 1, who typically require a 48-week course of
therapy. In genotype 1 patients failing to achieve 12-week EVR,
discontinuation of therapy is recommended. This not only pre-
vents the patient from suffering from subsequent side effects but
also generates considerable cost savings [25]. Economic analyses
have shown reductions in the cost of lifelong antiviral drugs of
about 45% with the use of the 12-week stop rule in patients
receiving PEG plus RBV [10].
Another significant follow-up that many services and patients
do not receive is the virologic assessment at the end of therapy.
This follow-up is essential to check the effectiveness of the
treatment, to evaluate the service, and for epidemiological data
and the management of health care services.
Administration of Injectable Drugs
IFN plus RBV is administered three times a week; therefore, its
cost is higher in comparison to PEG plus RBV (once a week). The
administration of injectable drugs is very important as many
patients do not have the ability to administer these drugs
themselves. Moreover, some patients do not have an adequate
place to store drugs at home.
One advantage of administering injectable drugs in specialist
clinics is the ability to control the allocation of antiviral drugs;
this is especially the case for PEG 2a where doses are calculated
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following up hepatitis C patients in Brazil (Rio Grande do Sul State)
showed savings of R $1,300,000 a year (approximately US $600,000)
as a result of controlled distribution of antiviral drugs to 395 follow-
up patients with genotype 1 chronic hepatitis C [27].
Outpatient Visits
The guidelines for HCV infection treatment in Brazil state that
specialist physicians should care for all patients. During treat-
ment other physicians are necessary because of side effects.
Moreover, pharmaceutical follow-up is necessary to provide
support to therapy and improve rates of adherence. Nursing staff
members are responsible for administering injectable drugs and
providing orientation about continuous follow-up.
Service provision by these professionals is included in the
direct cost. Within the public health system in Brazil, however, it
is very difficult for patients to access all these professionals. It is
important to note that for therapy with PEG the cost of providing
multidisciplinary care is less than 2% of the total direct cost of
treatment.
The total therapy cost in the German context for IFN plus RBV
is h16,433 and for PEG plus RBV is h25,028. Outpatient visits plus
laboratory tests cost h355 and h382, respectively, which also
represents around 2% of the total cost of treatment [28].
Studies show that patients are more likely to adhere to and
complete therapy when there is ongoing support by a clinical
team [12]. A multidisciplinary approach to supplement the role of
the physician can enhance patient education, and can include
family, nurses, pharmacists, nurse practitioners, and physician
assistants [22]. The pharmacy, for example, can facilitate adher-
ence by the use of pill organizers, accessible refills, and remin-
ders and by identifying adverse events [11,22].
Follow-up of patients should be carried out in specialist
clinics. Specialists have greater knowledge of current guidelines
for treating HCV infection and are better trained to meet the
needs of patients in relation to appropriate dosing, follow-up, and
education, as well as being more capable of managing nonre-
sponders, nonadherence, and side effects [25].
Ideally, a multidisciplinary team including experts in addic-
tion medicine, psychologists, and psychiatrists should care for
patients. Physicians must carefully weigh up the potential ben-
efits and risks of therapy for each individual, deciding on the best
predictor of treatment response.
Patient adherence to prescribed antiviral therapy enhances SVR
rates [13] and therefore the possibility of preventing advanced liver
disease [24,26]. Available data indicate that patients who are adher-
ent and receive at least 80% of their total PEG and RBV doses for at
least 80% of the duration of treatment will have significantly higher
rates of SVR than do patients with lower levels of adherence [11].
Patient education is the key to adherence. The prescriber or
other health care professional should assess the patient for
comorbidities or contraindications to therapy. Implementation
of system-wide patient education programs on all aspects of HCV,
and drug therapy in particular, can maximize benefits of available
therapies and help health plans achieve optimal results with the
limited resources available [29]. Other measures that may
improve adherence are frequent clinic and telephone follow-
ups, visits and access to support groups, printed information, and
self-monitoring devices [11].
It is important to be able to discuss the probability of cure
before starting treatment, and how this relates to the ability of
the patient to tolerate and complete the proposed course of
treatment. Patients must be informed of the potential side effects
of interferon-based therapies, how frequently they occur, their
severity, and how they can be managed. Optimism should be
emphasized, with assurances that most side effects, such asinterferon-related depression, can be managed by dose reduction
or other measures without the need to discontinue therapy [22].Hospitalization
The frequency of hospitalization is relatively low and is related to
side effects as a result of HCV infection treatment. Because of the
length of treatment and the frequency of side effects, the cost of
hospitalization with PEG plus RBV was more expensive than with
IFN plus RBV. Adequate follow-up and early care of side effects
can prevent hospitalizations. This demonstrates the importance
of patient follow-up by a multidisciplinary team.
A study using inpatient data from the Health Care Cost and
Utilization Project, outpatient data from the National Ambulatory
Medical Care Survey, and drug data from the Verispan Source
Prescription Audit analyzed the recent growth in the use of
health care resources among HCV infection patients by age
group, and found average annual increases of 25% to 30% for
hospitalizations, charges, hospital days, and physician visits [5].Total Estimated Budget
This is a preliminary study based on data from a sample of
patients in one particular state in Brazil. Costs in other states
may differ. However, using this data as a sample, the estimated
budget to treat 10,000 patients was calculated at more than US
$90 million, with antiviral drugs alone representing 88.2% of the
total cost. The cost of follow-up and support to patients is
minimal compared with the cost of antiviral drugs. In the case
of the Brazilian public health system, savings could be made by
providing adequate follow-up to patients undergoing HCV infec-
tion treatment. First, savings in resources could be made, result-
ing in improved cost-effectiveness. Second, further treatment
could be avoided. Third, adequate follow-up may reduce hospi-
talizations and adverse events rates. Further analyses, however,
are needed to calculate these savings.
Despite what is stated in the Brazilian guidelines, there are
barriers to providing adequate follow-up related to the different
responsibilities of government authorities. The Ministry of Health
funds antiviral drugs while the funding of care and follow-up,
including diagnostic tests and outpatient visits, is the responsi-
bility of municipal governments.
Greater identification and effective treatment of HCV-infected
patients, which would also reduce future HCV-related costs, can
be facilitated by well-planned education programs for primary
care providers. Furthermore, specialists are able to better ensure
effective treatment and follow-up. Implementation of methods to
ensure optimization of therapy can help attain therapy goals and
reduce long-term treatment costs. These include measures to
enhance adherence to therapy, close monitoring, and use of the
12-week stop rule. Enlisting the services of a specialist pharmacy
is another way of maximizing the efforts of health planning to
help patients achieve SVR, reducing long-term complications [25].
The present study has some limitations. The resources used
were estimates from different studies in the state of Santa
Catarina. The costs are exclusively based on the Brazilian
National Health System’s database and reflect the Brazilian
health care system. We did not take into account expenditure
directly on the part of the patient or private health plans. Some
figures from the public health system include only the cost of
procedures and not the monthly cost of physicians’ salaries, for
example.
We cannot guarantee that the drugs cost for the treatment of
side effects obtained from the municipality of Florianopolis is
representative of the country. The data, however, were taken
from a specialist clinic for HCV infection treatment.
Table 1 – Total direct cost (US $) of treatment for hepatitis C per patient with interferon plus ribavirin (IFN), peginterferon 2a
180 lg plus ribavirin (PEG 2a), and peginterferon 2b 120 lg plus ribavirin (PEG 2b).
IFN PEG 2a PEG 2b
Antiviral drugs 303.29 9,447.68 11,387.23
Epoetin alpha 110.06 220.13 220.13
Colony-stimulating factor 47.94 95.88 95.88
Other drugs 1.69 3.39 3.39
Initial diagnostics tests 260.23 356.26 356.26
Follow-up diagnostic tests 91.02 249.69 249.69
Injectable drugs application 25.86 17.24 17.24
Visits to physician specialist 28.50 39.90 39.90
Visits to nutritionist 0.20 0.41 0.41
Visits to psychiatrist 0.45 0.91 0.91
Visits to dermatologist 0.65 1.30 1.30
Pharmacotherapeutic follow-up 21.55 43.09 43.09
Nursing care 86.18 172.37 172.37
Hospitalization 4.93 9.86 9.86
Total 982.25 10,658.08 12,597.63
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estimate the use of resources. For some resources we assumed
the same proportion of cost between PEG and IFN treatments. It
was also difficult to obtain certain information from the State
Health Department, such as hospitalization data.
We included only direct medical costs. We have not included
costs of transport, reduced productivity, or absence from work.
Brazil does not have a homogenous pricing reference for
complementary expenses with direct costs. For example, amounts
attributed to the treatment (or follow-up) of patients with chronic
HCV infection may differ when considering routine treatment in a
reference clinic in a major city as opposed to a rural practice.
It is known that the rate of compliance to guidelines by health
care providers in Brazil is low. Patients dependent on the public
system have difficulties in accessing exams, drugs, and appoint-
ments with physicians. However, private health care patients are
monitored through closely followed procedures and individual
follow-ups. From a public health system perspective, it is impor-
tant to note that diseases cannot be cured by the simple
distribution of medication. It is necessary to improve the rates
of cure to achieve more efficiency in the system.
Despite the limitations, there are merits to our approach, as
pharmacoeconomic analysis must be adapted to the local reality.
Furthermore, we are not aware of another study that collects data
on the direct cost of treatment of hepatitis C in Brazil from a
public health perspective.Conclusions
According to the Ministry of Health figures, 90% of the annual
total cost of hepatitis C treatment is spent on antiviral drugs. The
cost of follow-up and support to patients is minimal compared
with the cost of antiviral drugs. In the case of the Brazilian public
health system, savings can be made by providing adequate
follow-up for patients undergoing HCV infection treatment.
PEG 2a or 2b combined with ribavirin, the current standard
care procedure, is effective in producing SVR in about half of the
patients with chronic HCV infection. Optimizing the use of these
antiviral agents, and the overall management of HCV infection, is
essential to ensure that the best possible patient outcomes are
achieved while long-term health care costs are minimized.
We need to be sure that the best care to patients with the
most efficient use of health care resources is being provided. The
12-week stop rule is one specific measure that can minimizecosts for patients who do not achieve EVR. Specialist pharmacies
can extend access of patients to clinician services to help ensure
adherence and intended outcomes of therapy. Methods to
increase treatment effectiveness and potentially reduce HCV-
related costs are necessary in Brazil.
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